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Abstract
In this paper, we outline a principled approach to estimate an individualized treat-
ment rule that is appropriate for data from observational studies where, in addition to
treatment assignment not being independent of individual characteristics, some char-
acteristics may affect treatment assignment in the current study but not be available
in future clinical settings where the estimated rule would be applied. The estimation
framework is quite flexible and accommodates any prediction method that uses obser-
vation weights, where the observation weights themselves are a ratio of two flexibly
estimated propensity scores. We also discuss how to obtain a trustworthy estimate
of the rule’s population benefit based on simple propensity-score-based estimators of
average treatment effect. We implement our approach in the R package DevTreatRules
and share the code needed to reproduce our results on GitHub.
1 Introduction
Precision medicine strives to leverage an individual’s specific characteristics to determine the
most beneficial course of treatment for that individual. In this paper, we consider the practice
of precision medicine in settings that present two particular sets of challenges: 1) data
come from observational studies where individual characteristics may influence treatment
assignment; and 2) the data at hand may measure individual characteristics that will not be
available in future clinical settings. As we summarize in Table 2, there are statistical methods
to account for the observational study design in 1) but they do not account for the subtlety
regarding variable roles in 2), and they often lack a user-friendly software implementation
that would allow practitioners to reliably apply them.
Some characteristics that affect treatment recommendation in a particular study may
be unavailable in future clinical settings, while other characteristics that did not directly
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affect treatment assignment may nonetheless be informative about treatment response in
future clinical settings. For example, some information that influences treatment assignment
(e.g. prognosis) may be measured subjectively in a given observational study and not be
measured in that same manner in clinical settings outside the scope of the study; such a
variable directly affects treatment assignment in the observational study but cannot directly
influence treatment recommendations in future clinical settings. On the other hand, some
available characteristics may not be interpretable in a clinical setting if there is a lack of
scientific knowledge about their role in a disease pathway (e.g. gene expression levels); such
characteristics do not directly affect the treatment decisions of clinicians but nonetheless
may be predictive of treatment benefit. Each of these variable types should be handled
differently by statistical methods that require distinct prediction of treatment assignment
and prediction of outcome, but past statistical methods have not pointed out the distinction.
We propose a principled framework (along with a user-friendly implementation in the
R package DevTreatRules, available on CRAN) that appropriately handles these distinct
variable when developing and evaluating a treatment rule based on data from an observational
study where treatment is not independent of individual characteristics. A treatment rule
is a function that recommends treatment based on individual characteristics; to be useful
to practitioners, a treatment rule must appropriately handle individual characteristics as
they are actually observed in clinical settings. Our framework yields a treatment rule that
accounts for the clinically distinct roles of individual characteristics in an interpretable way by
asking two simple questions – 1) Which characteristics will be measured in the same manner
in future settings where the estimated rule would be applied? 2) Which characteristics
potentially influence treatment assignment and thus must be accounted for as confounders?
– that reflect clinical rather than statistical expertise. Our framework also places a clear
emphasis on developing and evaluating the treatment rule on independent datasets which is
also absent from other papers in the treatment rule literature, as discussed in Section 4.
2
2 Previous Work
The framework presented in this paper draws on two previous bodies of work: 1) literature
on estimating treatment rules;and 2) tools from the causal inference literature that describe
how to estimate the average treatment effect (ATE) in study designs where treatment is not
randomized. There is notable overlap between these two topics even if the connection is not
always made explicit in the literature; nearly all methods for estimating treatment effect that
are appropriate in settings with non-randomized treatment rely on the inverse-probability-of-
treatment weighting (IPW) approach to balance observed confounders across the treatment
groups. The propensity score (the probability of treatment, conditional on individual char-
acteristics) has played a vital role in facilitating reliable comparisons of outcomes across
treatment groups in non-randomized studies at least back to Rosenbaum and Rubin (1983).
Austin (2011) presents an excellent and accessible overview of the ATE derived from the
causal inference literature and how it informs propensity-score-based estimation strategies
for non-randomized treatment assignment (e.g. the IPW method).
In this section, we highlight previous work on estimating treatment rules and we defer
discussion of the causal inference literature to Section 6.1, where we can more clearly show
how it shapes the target parameter of interest that is critical to our framework.
There is active statistical research on methods to predict the most beneficial treatment
option for a specific individual, in line with the objectives of precision medicine. An existing
approach generally belongs to one of two categories, either indirect or direct.
Indirect approaches (e.g. Kang et al. (2014); Cai et al. (2011); Lu et al. (2013); McK-
eague and Qian (2014); Ciarleglio et al. (2015)) typically assume structure on the regression
function linking the conditional mean outcome to individual outcomes and a treatment indi-
cator. The ideal treatment assignment for a individual is then inferred by predicting his or
her expected outcomes across possible values of the treatment variable using the regression
model, and choosing the treatment option with the most desirable predicted outcome (e.g. a
larger mean time until relapse or a smaller probability of 5-year relapse). In Lipkovich et al.
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(2017), indirect approaches are given the label “global outcome modeling”. As detailed in
Section 6, our framework is an indirect approach.
On the other hand, direct methods are motivated by optimizing performance of the treat-
ment rule itself in a population of interest rather then optimizing the accuracy of predicted
outcomes and then using each individual-level predicted outcome to decide which treatment
to assign (which would be the case with an indirect method). That is, these methods directly
estimate an optimal treatment rule rather than prioritizing estimation of the expected out-
come conditional on individual characteristics and treatment assignment (i.e. a regression
function), and then taking the additional step of assigning an individual to the treatment
with the most desirable predicted outcome.
Direct methods generally seek the treatment rule within a particular class of allowable
rules that maximizes an estimate of clinical benefit, and have the appealing motivation
of not being vulnerable to mis-specification of the regression function predicting outcome
based on individual characteristics (though direct methods must still make other modeling
assumptions to which they are sensitive). Lipkovich et al. (2017) present an outstanding
recent survey of statistical methods for estimating treatment rules in RCTs; direct methods
are part of that review’s “optimal treatment regimes” category. Zhang et al. (2015) pre-
specify that the treatment rule must be a nested sequence of “if, then” statements with one
or two individual characteristics involved in each statement. Zhang et al. (2012b) take a
similar approach but instead use a regression model to dictate the rule’s structure.
Other direct methods make less restrictive assumptions about the form of the treatment
rule at the cost of interpretability of the rule. Zhao et al. (2012) propose outcome-weighted
learning (OWL), which defines the optimal treatment rule as the solution to a weighted
classification problem whose solution can be approximated using a modified form of support
vector machines (SVM), a well-established statistical learning tool (Hastie et al., 2008). As
noted by Zhang et al. (2012a), OWL can be viewed as part of a general weighted-classification
framework for estimating a treatment rule, so any classification method that accommodates
4
observation weights (e.g. classification trees or penalized regression (Hastie et al., 2008)) is a
viable alternative to SVM in the estimation stage of OWL. The interactions-based procedure
from Chen et al. (2017) based on the earlier work of Tian et al. (2014) is a recent example
of a promising direct approach to estimating treatment rules with even greater flexibility.
Importantly, as mentioned in Lipkovich et al. (2017), some existing direct and indirect
methods for estimating treatment rules are adaptable to observational study designs where
treatment assignment is not independent of individual characteristics by accommodating
the IPW approach (Austin, 2011), which re-weights observations by the inverse of their
estimated propensity scores so clinically observed confounders are roughly balanced between
the treatment groups. The IPW adjustment thus allows for a sensible direct comparison
of mean re-weighted outcomes across treatment groups that is reflective of the underlying
population where the rule would be applied in the future. There is no consensus among
researchers on whether the direct or indirect approach to estimating treatment rules yields
superior results.
3 Categorization of Individual Characteristics
We propose partitioning each individual characteristic collected in an observational study
(aside from outcome and treatment variables) into the four clinically distinct categories
shown in Table 1: CTI , CTN , CNI , or CNN , where the abbreviations in each superscript tell
us whether each characteristic (C) affects treatment assignment in the current study (TN),
is expected to be observed in independent studies (NI), both (TI), or neither (NN). This
helps make explicit (as is not done in previous work) that only the CTI and CNI variables are
viable candidates for inclusion in a treatment rule because the remaining CTN and CNN will
not be available in future clinical situations where a proposed treatment rule would be
implemented. Here is a brief example of how each variable type may present itself in a
hypothetical observational study:
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1. Example of CTI : Age. In the study population, physicians might have been more
likely to recommend treatment to older individuals. In independent clinical settings,
we are confident that age can be reliably measured on the same scale.
2. Example of CTN : Center-specific measure of prognosis. In the study popula-
tion, clinicians may have been more likely to recommend treatment to individuals with
a poor prognosis as estimated by a center-specific set of guidelines (e.g. a hospital’s
standard rule-of-thumb procedure based on their specific doctors’ prior experiences
with individuals from the population). In independent clinical settings taking place
in different centers, clinicians would not estimate an individual’s prognosis with that
same center-specific approach.
3. Example of CNI : Gene expression levels. In the study population, individuals’
gene expression levels may have been measured but clinicians did not consider the
information when recommending treatment due to a lack of scientific knowledge about
the genes’ roles in disease progression and response to treatment. In independent
clinical settings, gene expression levels might still be reliably measured and would be
eligible to inform treatment decisions if a newly developed treatment rule suggests their
importance or if other scientific knowledge becomes available in the interim.
4. Discussion of CNN : CNN consists of variables in a dataset that are believed to have no
role in influencing treatment and cannot be reliably collected in future clinical settings;
the variables in CNN are not of interest to development or evaluation of treatment rules.
An example could be a study ID variable.
It will be useful in later sections to define: CI ≡ (CTI , CNI ) as all observed individual
characteristics that are also expected to be observed in independent clinical settings. Also,
we define R as a subset of the variables contained in CI that the researcher believes may
affect response to treatment and thus are viable candidates for a treatment rule. We also
define CT ≡ (CTI , CTN ) as all individual characteristics that potentially affect treatment
6
in the current observational study. In the BuildRule() and EvaluateRule() functions
from DevTreatRules, users are required to provide the characteristics in CT with the ar-
gument names.influencing.treatment and the characteristics in R with the argument
names.influencing.rule. That is, individual characteristics are never entered into the
package without first being categorized by the user.
4 Gaps in the Literature
To help situate this paper in the literature, Table 2 presents a selection of direct and indirect
methods for estimating treatment rules and whether each satisfies five criteria. As seen in
Table 2, none of these selected previous methods (and, to our knowledge, no other method in
the literature) distinguishes between observed individual characteristics using the clinically
meaningful categorization of whether they will be available in future clinical settings (in
which case they are sensible candidates for building the treatment rule) or are not expected
to be available in future settings (in which case they should not be used to build the rule).
The lack of available R packages implementing previous approaches is also re-enforced by
Table 2.
We believe that our work fills a gap in the literature by providing practitioners with a
principled approach to appropriately classify variable types as in Table 1 and by provid-
ing the user-friendly DevTreatRules, which actually requires users to make their clinically
informed variable categorizations when they apply the work to real data (using the argu-
ments names.influencing.treatment and names.influencing.rule in its BuildRule()
and EvaluateRule() functions). In addition, although it is not considered in the table,
none of those previous methods explicitly integrates data-splitting to ensure that the stages
of development/evaluation (or development/validation/evaluation) of a treatment rule are
conducted on independent datasets to yield a trustworthy estimate of the rule’s population
impact; we emphasize data-splitting throughout this paper and in the formalized procedure
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in Section 6.2.
5 Motivating Example
Suppose an observational study recruits individuals with a particular type of cancer from a
single hospital and collects baseline information at the time of recruitment. Further suppose
that, for each individual, this observational dataset measures: months until relapse (Y ); an
indicator of receiving standard-of-care (T = 0) or additional chemotherapy in addition to the
standard-of-care option (T = 1); age; a measure of day-to-day life functioning; and expression
levels of p genes. For simplicity, we assume that clinicians decide to treat individuals based
only on age and day-to-day life functioning. In contrast, the gene expression levels are
unobservable by clinicians due to high cost and are also uninterpretable due to a lack of
scientific knowledge about the genes’ roles in disease progression and response to treatment.
In this illustrative example, we assume no unmeasured confounding.1
In practice, there are two alternative scores used to an individual’s day-to-day functioning.
One is the Eastern Cooperative Oncology Group (ECOG) Performance Status, a grade
ranging from 0 to 5 where a lower grade represents fewer restrictions in day-to-day life
(Oken et al., 1982). The other is the Karnofsky Performance Status (KPS), an 11-point scale
ranging from 0 to 100 where a lower value represents more day-to-day restrictions (Karnofsky,
1949). As an added complication, we suppose that in this particular observational study day-
to-day functioning is measured using the ECOG score, but that KPS is used instead of ECOG
score in future clinical settings where we would like to apply our developed treatment rule in
the future.2 In contrast, we assume an individual’s age and p gene expression measurements
1In practice, however, gene expression levels may serve as surrogates for unobserved confounders. For
instance, it is estimated that 20%-30% of breast cancer cases consist of an over-expression of human epi-
dermal growth factor receptor type 2 (HER2), which can be targeted by additional treatment that inhibits
HER2 generation (Joensuu et al., 2006; Hudis, 2007). For types of cancer with unknown subtypes the gene
expressions conducted in an observational study may be associated with (but not explicitly define, as with
HER2) disease subtypes that may be more or less vulnerable to disruption by the treatment mechanism.
2Although in practice there are mappings between ECOG and KPS, for illustrative purposes here we
treat them as variables representing the same individual characteristic using qualitatively distinct scales
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will be reliably collected in future clinical settings.
Figure 1 shows our hypothesized data-generating mechanism. We have the following
variable types in this example: CNI = (gene1, . . . , genep), C
TI = age, CTN = ECOG, CT =
(age, ECOG), and R=(gene1, . . . , genep). The KPS variable is a potential confounder only
in independent clinical settings (but not the current dataset) and as such KPS plays an
important role in evaluation of the rule that we discuss in Section 6.3.
We are interested in building and evaluating a classifier, for future individuals, that indi-
cates their optimal treatment based on their gene expression values. However, in constructing
this classifier, we must account for a) the confounding influence of age and day-to-day func-
tioning on the relationship between treatment and months until relapse; and b) the distinct
approaches to measuring day-to-day functioning across different clinical settings (based on
use of ECOG or KPS).
6 Method
Here, we provide some theoretical justification for how the individual characteristics CTN ,
CTI , and CNI should be used to develop a treatment rule and evaluate the rule’s benefit. We
will refer to this method as the split-regression approach to developing a treatment rule. As
in Section 5, we will interpret T as an indicator of receiving a new treatment in addition to
standard-of-care (T = 1) or standard-of-care alone (T = 0) and outcome Y as months until
relapse.
(e.g. higher scores mean lower quality of life for KPS but a higher quality of life for ECOG) and suppose
they are non-conformable.
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6.1 Estimating the Rule
6.1.1 The Target Parameter
Our goals are 1) to identify a subset of the population – in terms of R, the researcher-chosen
subset of individual characteristics that are valid candidates for inclusion in a treatment
rule – we expect to benefit from treatment and 2) to estimate the extent of benefit in this
subpopulation.
Our estimation strategy begins with a foundational parameter of interest, E[Y 1 − Y 0],
often called the average treatment effect (ATE) in the causal inference literature, where in
potential outcomes notation, Y 1 is the months until relapse that would have been observed
had an individual received treatment and Y 0 is the months until relapse that would have
been observed had the individual received standard-of-care (see Kennedy (2015) for an ex-
cellent review). So the ATE gives the average difference in months until relapse when an
individual in the population of interest receives treatment instead of standard-of-care. The
ATE is identifiable under three assumptions: 1) consistency : T = t implies Y = Y t; 2) no
unmeasured confounding : conditional on observing CT , T is independent of Y t; 3) positivity :
if P (CT > 0) then P (T = t | CT = cT) > 0, for t = 0, 1.
As originally developed by Robins (1986), if the consistency, no unmeasured confounding,
and positivity assumptions hold, then the ATE is equivalent to
ψ ≡
∫
CT
{
E
[
Y | CT , T = 1]− E [Y | CT , T = 0]} dP (CT ), (1)
which is known as a “g-computation” formula in the causal inference literature. To estimate
whether treatment offers a superior outcome for an individual with characteristics R = r,
we simply consider the subgroup-specific ATE
E[Y 1 − Y 0 | R = r]. (2)
The subgroup-specific ATE in (2) is also a parameter of interest in Cai et al. (2011), the
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previous method that we believe is most similar to the one we discuss in this section. The
practical limitations of Cai et al. (2011) on which this paper expands are that it was designed
only for the RCT setting, did not explicitly distinguish between individual characteristics
CT and CI , was not implemented in an R package, and did not share code to guide users
in implementation.
To estimate (2) in the setting of non-randomized treatment assignment, the
g-computation formula in (3) similarly changes to
ψ(r) ≡ ∫
CT
{
E
[
Y | CT ,R = r, T = 1]− E [Y | CT ,R = r, T = 0]} dP (CT |R = r) , (3)
which estimates the average treatment effect for individuals with characteristics R = r that
will be observable in future clinical settings.
From (3), we see that we should treat the individuals defined by Ω+ = {r | ψ(r) > C}
for C ≥ 0. If R were a set of gene expression levels and C = 0, for example, then Ω+ would
be the subset of gene expression levels for which treatment increases the expected number of
months until relapse. The expected improvement in months until relapse among the treated
subpopulation is
∫
r∈Ω+ ψ(r)dP (r).
6.1.2 Estimating the Target Parameter
One possible approach for estimating the modified ATE in (3) would be to separately estimate
E
[
Y | CT ,R, T = t] for t = 0, 1 and estimate dP (CT |R), then plug these estimates into
(3); however, this approach requires estimation of a conditional density function that is only
practical when the individual characteristics in R are perhaps one or two categorical variables
with very few levels while in other situations the approach would prescribe a very complicated
and highly variable average (as described in greater detail in Chapter 3 of Varadhan and
Seeger (2013), for example).
Our goal is now to re-write our estimation target (3) as a simple minimization problem
that does not involve estimation of the conditional density dP (CT |R). We begin by re-
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stating (3) as ψ(r) = f1(r)− f0(r), where, for t = 0, 1,
ft(r) =
∫
CT
E
[
Y | CT ,R = r, T = t] dP (CT |R = r). (4)
We emphasize that (4) is exactly equivalent to (3), just with altered notation. By taking
the perspective in (4) we only need to estimate ft(r) for t ∈ {0, 1} to obtain an estimate of
the ψ(r) in (3). As derived in the Appendix, it turns out that ft(r) can be written as the
minimizer
ft(r) ≡ arg min
f∈F
∫
R
∫
CT
wt(r, c
T)L(y, f(r))dP (y, cT, r|T = t), (5)
where L(y, f(r)) is any function of y and r such that its conditional expectation E[y | f(r)]
is the minimizer – which in practice we may think of as a “canonical” loss function such as
squared-error loss for a continuous y or logistic loss for a binary y – and F is a function class
in which the rule is known to lie (one possibility could be `1(P ), the space of all absolutely
integrable functions over P ).
A natural weight function wt(r, l) that can be used turns out to be
wt(r, c
T) =
P (T = t|R = r)
P (T = t|R = r,CT = cT) . (6)
We note that the standard IPW observation weight would replace the numerator of (6) with
a 1. In fact, the weight function in (6) is closely related to the “stabilized weights” proposed
by Robins et al. (2000), which in this case would be P (T = t)/P (T = t|CT = cT,R =
r). The weight function implied by Robins et al. (2000) differs from (6) by the latter’s
extra conditioning on R = r, the subset of individual characteristics that are potentially
informative inputs to the treatment rule.
The derivation in (5) implies a natural estimate of ft that is not complicated by the
dimensionality of R: the minimizer of the weighted sample average over individuals in the
T = t group
f˜t ≡ argminf∈F
1
nt
∑
Ti=t
(
P˜ (T = t | ri)
P˜ (T = t | ri, cTi)
)
L(yi, f(ri)), (7)
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where nt is the number of individuals in the group T = t, P˜ (T = t | ri) is an estimate of
P (T = t | R = r), and P˜ (T = t|ri, cTi) is an estimate of P (T = t | R = ri,CT = cTi).
We note that the estimate f˜t is only reasonable if F is a suitably constrained class (e.g. a
class with smoothness constraints, like a Sobolev class or class with bounded total variation
(van de Geer, 2000)).
However, the formula (7) suggests another approach for estimation of ft: Instead of
necessarily solving a formal empirical minimization as in (7), one might use any predictive
modeling method that accommodates observation weights (e.g. generalized linear models,
lasso, ridge regression, boosted trees, neural nets, and many others). All of these methods
can be written as, either exactly or approximately, minimizing a weighted least-squares-like
loss over a, potentially complicated, function class. Many of the methods indicated in Table
2 as being flexible in fact only support penalized or non-penalized weighted regression; our
framework supports much more flexibility by moving beyond regression-based methods.
Now that we can estimate ψ˜(r) = f˜1(r) − f˜0(r), we can simply form the treatment
rule as B˜(r) ≡ I
[
f˜1(r)− f˜0(r) > 0
]
, which recommends treatment to an individual with
characteristics R = r if the estimated months until relapse is higher under T = 1 than
T = 0.
6.2 The Recipe
The work in Sections 6.1 yields the following procedure applied to a development dataset
(D1), which must be independent of the evaluation dataset (D2); we use the superscripts D1
and D2 to emphasize the dataset on which the accompanying estimate is formed.
1. Use the scientific knowledge underlying D1 to partition observed individual character-
istics into the four categories presented in Table 1: CTI , CTN , CNI , and CNN . Also
form CT = (CTI , CTN ), CI = (CTI , CNI ), and form the potential inputs for the
treatment rule R ⊆ CI .
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2. For observations i = 1, . . . , n on D1:
(a) Choose a prediction method and estimate the propensity scores P˜D1(T = 1 | R =
ri) and P˜
D1(T = 1 | R = ri,CT = cTi).3
(b) Compute the weights W˜t(R = ri,C
T = cTi) =
P˜D1(T=t|R=ri)
P˜D1(T=t|R=ri,CT =cTi) , for t = 0, 1.
(c) Choose a prediction method that accommodates observation weights (e.g. gen-
eralized linear regression, lasso, boosted trees, and many others) and estimate
f˜0 and f˜1 as suggested by (7). For example, weighted linear regression with a
continuous response would yield, for observations i = 1, . . . , n on D1,
β˜D10 ≡ arg min
β∈Rp
1
n0
∑
Ti=0
W˜0(ri, c
T
i)(yi − r>i β)2, (8)
β˜D11 ≡ arg min
β∈Rp
1
n1
∑
Ti=1
W˜1(ri, c
T
i)(yi − r>i β)2, (9)
where W˜t(R = ri,C
T = cTi) =
P˜D1(T=t|R=ri)
P˜D1(T=t|R=ri,CT =cTi) for t = 0, 1 and where we
define f˜D10 (r) ≡ r>β˜D10 and f˜D11 (r) ≡ r>β˜D11 .
3. Form the treatment rule B˜(r) ≡ I
[
f˜D11 (r)− f˜D10 (r) > 0
]
, where I(·) is the indicator
function.
4. Use scientific knowledge underlying D2 to select the potential confounders CT, eval . 4
5. For observations j = 1, . . . ,m on D2:
(a) Assign the recommended treatment with B˜D2j ≡ B˜D2(rj).
(b) As discussed next in Section 6.3, form the IPW-based estimators of the ATE in
the test-positives and in the test-negatives using (10) and (11), respectively.
3It can be useful to truncate estimated propensity scores so they are not too close to 0 or 1 (which can
lead to very large observation weights); a default setting in our software implementation truncates estimated
propensity scores to stay between 0.05 and 0.95, but this choice can be overwritten by the user.
4Ideally, D1 and D2 would be datasets from separate observational studies where D2 independently
samples from the population where future intervention would take place, but D1/D2 may also be a random
partition of data from a single observational study; in the latter case, we will have CT, eval = CT . The
DevTreatRules package supports developing and evaluating rules in either situation.
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6.3 Evaluating the Rule
Now we define CT, eval as the set of potential confounders of the association between treat-
ment and response in the evaluation dataset. We note that if the development and evaluation
datasets are partitions of the same observational dataset then the variables in CT, eval will
be identical to those in CT , but this need not be the case when development and evaluation
are carried out using data from separate studies. For example, in the motivating example
from Section 5, we had CT =(age, ECOG) but CT, eval = (age, KPS).
To evaluate the the developed rule B˜ using Section 6.2, we can use an estimate of the
ATE in the test-positives population with the IPW-based estimator (see e.g. Austin (2011))
ÂTE
+ ≡ 1
N+
∑
{j | B˜(rj)=1}
tjyj
P˜ (T=1|CT, eval =cT, eval) − 1N+
∑
{j | B˜(rj)=1}
(1−tj)yj
P˜ (T=0|CT, eval =cT, eval) , (10)
where N+ is the number of test-positives. A small modification to (10) also estimates the
effect of avoiding treatment among the test-negatives:
ÂTE
− ≡ 1
N−
∑
{j | B˜(rj)=0}
tjyj
P˜ (T=1|CT, eval =cT, eval) − 1N−
∑
{j | B˜(rj)=0}
(1−tj)yj
P˜ (T=0|CT, eval =cT, eval) , (11)
where N− is the number of test-negatives. We note that we would expect (11) to be a
negative number for a rule that accurately identifies the test-negatives.
We can also form a simple estimator of the average benefit of the rule (ABR) in the
population from which our the evaluation dataset is a representative sample with
ÂBR ≡
(
N+
N+ +N−
)
ÂTE
+
+
(
N−
N+ +N−
)(
−ÂTE−
)
,
a weighted average of the benefit of receiving treatment the test-positives from (10) and the
benefit of avoiding treatment in the test-negatives from (11), respectively.
Alternatively one could estimate ATE with the estimator developed by Robins et al.
(1994) that is sometimes called the doubly-robust or augmented analog of (10); Lunceford
and Davidian (2004) present an excellent derivation and simulation study comparing different
estimators of the ATE. We chose to present only the IPW-based estimators for ease of
15
exposition.
6.4 R Implementation
The R package DevTreatRules implements this paper’s split-regression approach. In partic-
ular, the functions SplitData(), BuildRule(), and EvaluateRule() handle, respectively:
the development/evaluation partitioning of a dataset (or development/validation/evaluation
partitioning if model selection is also performed); the development of the treatment rule (in
dataset D1) as in steps 2-4 of Section 6.2; and the evaluation of the rule (in dataset D2) as
in steps 5-6 of Section 6.2. The vignette accompanying DevTreatRules walks through an
example of building and evaluating a treatment rule using the package, in a situation where
model selection is also performed using the CompareRulesOnValidation() function.
7 Simulations
We simulate data for a development sample of size n with the individual characteristics
Xi ∼ Uniform(0, 2), Li ∼ Bernoulli(0.5), Gi ∼ Normal(0, 1)
the treatment indicator
Ti | Li ∼
 Bernoulli(0.75), Li = 0Bernoulli(0.25), Li = 1,
and binary outcome
P (Yi = 1 | Xi, Li, Ti) =
 expit [β0,T=0 + β1,T=0Xi + γT=0Li] , Ti = 0expit [β0,T=1 + β1,T=1Xi + γT=1Li] , Ti = 1,
for i = 1, . . . , n, where β0,T=t, β1,T=t, γT=t ∈ R for t = 0, 1. Using the notation from Section
1, we would categorize CT = CT, eval = L and CI = R = (X,G).
Figure 2 depicts the relationship between P (Y | X,L, T ) and X, where the true response
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probability for the L = 1 group is shown with circles and for the L = 0 group with triangles.
The standard-of-care group is shown in blue and the treatment group is shown in orange. As
seen in Figure 2, the outcome (Y ) is more likely under treatment than under standard-of-
care for individuals with a value of X about 1.3 in both the L = 1 and L = 0 groups. Thus,
the optimal treatment rule would recommend treatment to an individuals with X > 1.3.
However, due to the confounding effect of L, an empirical average of the response-curves
for each treatment group (solid blue line and dotted orange line in the left panel of Figure
2) incorrectly suggests that there is no subset of individuals for whom treatment makes the
outcome more likely. On the other hand, the IPW approach (solid blue line and dotted
orange line in the right panel of Figure 2) uses a weighted average of response-curves, where
each weight is the IPW weight (based on L), to correctly identify the value of X (about 1.3)
where the response-curves cross.
In Table 3, we present the mean probability of the (desirable) outcome for a range of
development set sample sizes, specifying logistic regression (with R as the predictors) for
steps 2 in Section 6.2. The first row shows the mean outcome probability for rules built
using the split-regression approach described in Section 6.2. The second row reports the
mean outcome probability for a modification to the split-regression approach that “naively”
uses the incorrect sample averaging shown in the left panel of Figure 2 (i.e. it uses identical
observation weights in step 2 of Section 6.2).
The estimated outcome probabilities in the first three rows of Table 3 can be compared
to the benchmark value of 0.574 for the optimal rule (known from the data-generating mech-
anism) that perfectly assigns treatment to only those who benefit and withholds it from
those who do not benefit. We also compare to a rule that recommends everyone receive
treatment (which may be the prevailing policy when an available treatment is believed to be
uniformly effective) and to a rule that recommends no one receive treatment (which might
be the preferred strategy when the effectiveness of a proposed treatment has not yet been
established).
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Table 3 shows the advantage of using split-regression with IPW weights relative to the
“naive” uniform weighting: The bias of the naive approach forces the estimation of the
incorrect non-crossing response-curves shown with the solid lines in the left panel of Figure
2. In contrast, split-regression with the correct IPW weighting approaches the optimal
treatment rule with large enough sample size because it is estimating the crossing response-
curves in the right panel of Figure 2. The code used to perform the simulations is shared at
github.com/jhroth/simulations-split-regression.
8 Data Example: WHI-OS
We also illustrate the split-regression approach and compare it to alternatives by applying
the R package DevTreatRules to the Women’s Health Initiative Observational Study
component (WHI-OS). A detailed description of the study design and summaries of
baseline measurements for participants (postmenopausal women between the ages of 49
and 81 who were recruited for the WHI clinical trial but either declined to participate
or were later deemed ineligible) are available in Langer et al. (2003). We also present
summary tables of the variables we retained for analysis in the appendix. The GitHub page
github.com/jhroth/data-examplesplit-regression contains the R code needed to go
start-to-finish from loading the raw WHI-OS datasets (access to which requires additional
permission) to replicating our estimates in the evaluation subset.
Briefly, we aim to build a treatment rule to assign baseline hormone therapy (HRT) –
defined as currently using unopposed estrogen and/or estrogen plus progesterone at baseline
– to postmenopausal women if it will increase a woman’s probability of remaining free of
coronary heart disease (CHD) after 10 years and, in a separate analysis, if it will increase a
woman’s probability of remaining free of breast cancer after 10 years. All variables included
in our analysis besides the outcomes were measured at baseline. We used the “adjudicated”
outcome variables in the WHI-OS as described in Curb et al. (2003).
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We classified 4 categorical variables as belonging to CTN : education level, ethnicity,
family income, and how each participant heard about the study. We identified 31 self-
reported variables to make up CTI and we chose R = CTI , so there are 31 candidates to
be used as inputs in our treatment rule. We did not specify any variables as belonging to
CNI . In the Appendix, we present the complete list of these variables and simple summaries
including counts of missing values. We intend for this to be primarily an illustrative example
rather than a definitive claim about appropriate variable classifications in this study.
About 17.6% of the 94140 observations in the initial dataset had a missing value of at least
one variable in CT or R. Instead of conducting a complete-case analysis that would drop
observations with missing values, we used an IPW-based adjustment for missingness (Seaman
and White, 2013). Our shared code shows the details of our adjustment for missingness using
the additional.weights argument of the BuildRule() and EvaluateRule() functions in
DevTreatRules.
The top-half of Table 4 presents estimated ATEs and ABR in the validation set for
two split-regression specifications using the outcome of no breast cancer after 10 years:
one that used ridge regression for the propensity score and lasso for the rule, and another
specification that used logistic regression for both the propensity score and rule models. On
the validation set, none of the split-regression specifications for the outcome of no CHD after
10 years appeared to be an improvement over the naive strategy of treating no one and thus
none of those specifications were chosen. Since the estimated ATEs and ABR in Table 4
informed our model selection – in particular, we chose these models because their ABRs in
the validation set were relatively high – they do not serve as trustworthy estimates of ATE
and ABR in independent samples drawn from this population in the future.
The bottom-half of Table 4 presents the estimated ATEs and ABR in the evaluation set,
which did not inform model selection. Unfortunately, the 95% CI for estimated ATE among
the treated population contains 0 for both rules in the evaluation set; as a result, we do not
find evidence that either rule has identified a subpopulation of individuals who appear to
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benefit from treatment.
9 Discussion
We outlined a principled approach to classify the roles of variables collected in an obser-
vational study into clinically meaningful categories and, using that knowledge, to develop
a treatment rule along with a trustworthy estimate of the rule’s population benefit. Since
this paper is intended to be a practical guide to help practitioners go from start to finish in
estimating and evaluating treatment rules without getting bogged down by the onerous and
error-prone tasks of coding the method from scratch in statistical software, we implemented
our approach in the R package DevTreatRules and shared the code needed to reproduce our
simulations and data example on GitHub.
In a simple simulation study, we saw the benefit of estimating a treatment rule using this
paper’s preferred approach with IPW weighting compared to using uniform observational
weights that ignore the observational study design. In the WHI-OS data example, we used
the split-regression approach to develop a treatment rule that assigns baseline hormone
therapy to postmenopausal women if it is expected to increase their probability of remaining
free of coronary heart disease after 10 years or free of breast cancer after 10 years. With
the 10-year CHD outcome, split-regression did not estimate a rule with a positive estimate
of ATE in the treated subgroup on the validation set. With the 10-year breast cancer
outcome, however, split-regression did identify a rule that recommends HRT to about 18%
of women and, among this treated subpopulation, had an estimated 1.5 percentage-point
decrease in the probability of breast cancer. However, this 1.5 percentage-point decrease lacks
statistical significance (95% CI: −0.027, 0.068) and, as a result, we would simply recommend
not assigning HRT to any women in this population if the goal is to reduce 10-year breast
cancer incidence or 10-year CHD incidence. This null finding is, unfortunately, often a typical
result in the search for informative treatment rules with observational data.
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One notable limitation of this work is that, while the algorithm outlined in Section 6.2
is fairly general, the accompanying R implementation does not have as much flexibility (e.g.
the currently available estimation methods are linear/logistic regression and its lasso/ridge
counterparts); in future work we hope to expand the package to support more estimation
methods. Another limitation is that our data example is not publicly reproducible because
we are unable to share the underlying WHI-OS dataset; however, we do share the code that
will reproduce the data example for users who have access to the raw WHI-OS data files.
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Treatment
ECOG
(CTN )
Age
(CTI ) KPS
Years until
relapse
Gene
expression
levels
(CNI )
Figure 1: Potential data-generating mechanism. Each node shows a individual characteristic
(and, for those besides treatment and outcome, its corresponding variable type from Table
1 in parentheses)
Sample averaging Population averaging
Figure 2: Simulation scenario with n = 500, (β0,T=0, β1,T=0, γT=0) = (0,−0.55, 1.5), and
(β0,T=1, β1,T=1, γT=1) = (−1.4, 0.55, 1.5)
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Potentially influences treatment Observed in
in current study independent clinical settings
Yes No
Yes CTI CTN
No CNI CNN
Table 1: Proposed partitioning of individual characteristics in an observational study
Framework
Type of
approach
Accommodates
observational
data
Distinguishes
between
(CTI , CNI )
and (CTN )
Accommodates
a range of
statistical
learning
methods
R pack-
age
Shares code
to reproduce
simulations
or application
Zhao et al. (2012) Direct Yes No No Yes1 No
Zhang et al. (2012a,b) Direct Yes No Yes No Yes
Zhang et al. (2015) Direct Yes No No No Yes
Qian and Murphy (2011) Direct No No No No No
Chen et al. (2017) Direct Yes No Yes Yes2 Yes
Cai et al. (2011) Indirect No No Yes No No
Lu et al. (2013) Indirect No No Yes No No
Kang et al. (2014) Indirect No No Yes No Yes
McKeague and Qian (2014) Indirect No No Yes No No
Ciarleglio et al. (2015) Indirect Yes No No No Yes
This paper Indirect Yes Yes Yes Yes Yes
Table 2: Selected methods for estimating treatment rule
1Holloway et al. (2019)
2Huling et al. (2019)
Sample size in development set
Type of Rule 50 100 200 500 1000
Split-regression 0.543 0.553 0.562 0.57 0.572
Split-regression (naive, no weights) 0.552 0.554 0.553 0.55 0.549
Optimal rule 0.574 0.574 0.574 0.574 0.574
Treating all 0.479 0.479 0.479 0.479 0.479
Treating none 0.543 0.543 0.543 0.543 0.543
Table 3: Mean outcome probability, as a function of rule type and development set sample
size, averaged over 1000 replications and calculated in evaluation sets of size 10000
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Positives Negatives ATE in Positives ATE in Negatives ABR
Estimates on Validation Set
Split regression (ridge/lasso) 3544 15758 0.013 -0.051 0.044
Split regression (logistic/logistic) 3692 15610 0.021 -0.053 0.047
Treat no one (logistic/NA) 0 19302 NA -0.045 0.045
Estimates on Evaluation Set
Split-regression (ridge/lasso) 3408 15894 0.015 (-0.027, 0.068) -0.045 (-0.067, -0.031) 0.04
Split-regression (logistic/logistic) 3569 15733 0.002 (-0.049, 0.052) -0.048 (-0.07, -0.035) 0.04
Treat no one (logistic/NA) 0 19302 NA -0.05 0.05
Table 4: Summary of Selected Rules on the Validation and Evaluation Sets (Outcome: No
breast cancer after 10 years). The selected propensity method/rule method are in parentheses
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Appendix:
Using Propensity Scores to Develop and Evaluate Treatment Rules
with Observational Data
A Motivation for IPW Estimator of Average Treat-
ment Effect
We are starting with
ΨR ≡
∫
CT
{
E(Y | CT ,R, T = 1)− E(Y | CT ,R, T = 0)} dP theoretical(CT | R), (12)
and, focusing on the T = 1 group for a fixed R, we can write
Ψ(T = 1 | R) =
∫
CT
E(Y | CT ,R, T = 1) dP theoretical(CT | R), (13)
=
∫
CT
min
f∈F
{∫
Y
(y − f(R))2 dP actual(Y | CT ,R, T = 1)
}
dP theoretical(CT | R), (14)
= min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP actual(Y | CT ,R, T = 1) dP theoretical(CT | R). (15)
For random R, we have
Ψ(T = 1,R) ≡
∫
R
∫
CT
E(Y | CT ,R, T = 1) dP theoretical(CT | R) dP actual(R | T = 1)
=
∫
R
∫
CT
min
f∈F
{∫
Y
(y − f(R))2 dP actual(Y | CT ,R, T = 1)
}
dP theoretical(CT | R) dP actual(R | T = 1)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP theoretical(CT | R) dP actual(Y | CT ,R, T = 1) dP actual(R | T = 1)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP theoretical(CT | R) dP actual(Y | CT ,R, T = 1) dP actual(R | T = 1) dP
actual(CT | R, T = 1)
dP actual(CT | R, T = 1)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP
theoretical(CT | R)
dP actual(CT | R, T = 1) dP
actual(Y,CT ,R | T = 1). (16)
Since
P actual(CT | R, T = 1) = P
actual(CT ,R, T = 1)
P actual(T = 1 | R)P actual(R)
=
P actual(T = 1 | CT ,R)P actual(CT | R)P actual(R)
P actual(T = 1 | R)P actual(R) ,
=
P actual(T = 1 | CT ,R)P actual(CT | R)
P actual(T = 1 | R) ,
≡ pi(C
T ,R)P actual(CT | R)
pi(R)
,
we can rewrite (16) as
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Ψ(T = 1,R) ≡
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP
theoretical(CT | R)
dP actual(CT | R, T = 1) dP
actual(Y,CT ,R | T = 1)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP
theoretical(CT | R)pi(R)
pi(CT ,R)dP actual(CT | R) dP
actual(Y,CT ,R | T = 1)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 dP
theoretical(CT | R)
dP actual(CT | R) ·
pi(R)
pi(CT ,R)
dP actual(Y,CT ,R | T = 1)
If we assume dP theoretical(CT | R) = dP actual(CT | R) (i.e. representative sampling of
covariates, conditional on values of the biomarkers), then this becomes
Ψ(T = 1,R) =
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 pi(R)
pi(CT ,R)
dP actual(Y,CT ,R | T = 1). (17)
If we assume the propensity scores are known, then the plug-in estimator of (17) is
min
f∈F
1
N1
N∑
i=1
I(Ti = 1)
pi(Ri)
pi(CT i,Ri)
[Yi − f(Ri)]2 , (18)
where N1 =
∑N
i=1 I(Ti = 1). We note that (18) is weighted squared-error loss among T = 1
group with weights w1(C
T ,R) ≡ pi(R)/pi(CT ,R).
Similarly in the T = 0 group, the target parameter is
Ψ(T = 0,R) ≡
∫
R
E(Y | CT ,R, T = 0) dP theoretical(CT | R) dP actual(R | T = 1)
=
∫
R
∫
CT
min
f∈F
{∫
Y
(y − f(R))2 dP actual(Y | CT ,R, T = 0)
}
dP theoretical(CT | R) dP actual(R | T = 0)
=
∫
R
min
f∈F
∫
CT
∫
Y
(y − f(R))2 1− pi(R)
1− pi(CT ,R) dP
actual(Y,CT ,R | T = 0),
whose plug-in estimator, assuming the propensity scores are known, is
min
f∈F
1
N0
N∑
i=1
I(Ti = 0)
1− pi(Ri)
1− pi(CT i,Ri) [Yi − f(Ri)]
2 (19)
where N0 =
∑N
i=1 I(Ti = 0). We note that (18) is weighted squared-error loss among T = 0
group with weights w0(C
T ,R) ≡ (1− pi(R))/(1− pi(CT ,R)).
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B Evaluating the Rule
As described in the paper, a foundational target parameter in our framework is the average
treatment effect (ATE) in a subpopulation of individuals with characteristics R = r.
E[Y 1 − Y 0 | R = r], (20)
which under the assumptions of consistency, no unmeasured confounding, and positivity, as
detailed in Kennedy (2015) can be re-written as
ψ(r) ≡ ∫
CT
{
E
[
Y | CT ,R = r, T = 1]− E [Y | CT ,R = r, T = 0]} dP (CT | R = r) , (21)
which implies we should recommend treatment to individuals in the subgroup
Ω+ = {r | ψ(r) > 0} , (22)
which is known as the test-positives group. If R were a set of gene expression levels, for
example, then Ω+ would be the subset of gene expression levels for which treatment increases
the expected number of months until relapse. Again, the expected improvement in months
until relapse among this treated subpopulation is∫
r∈Ω+
ψ(r)dP (r). (23)
Similarly, treatment should not be recommended to individuals in the test-negatives subpop-
ulation defined by
Ω− = {r | ψ(r) ≤ 0} , (24)
and ∫
r∈Ω−
ψ(r)dP (r). (25)
would yield the average increase in months until relapse for the subpopulation that avoids
treatment.
To obtain a trustworthy estimate of how a developed treatment rule will perform for
individuals seen in future clinical settings, it is absolutely essential that development of the
rule and evaluation of the selected rule are performed independently. Chapter 7 (Model
Assessment and Selection) of Hastie et al. (2008) provides an excellent discussion of this
topic with regard to the predictive performance of model-based estimates. In brief, if the
development and evaluation datasets coincide then our evaluation of the treatment rule’s
benefit will be overly optimistic because it will reward the rule for incorrectly classifying
noise in the development dataset as signal that would persist when we apply the rule to
future individuals.
We can take the treatment rule B˜(r) – which gives us a mapping from an individual’s
particular characteristics R = r to a treatment recommendation – that was estimated on
a development dataset and apply it to the independent evaluation dataset to yield, for the
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neval individuals in the evaluation dataset indexed by i = 1, . . . , neval,
Ω˜+ =
{
ri | B˜(ri) = 1
}
, (26)
the test-positives subset of observations in the evaluation dataset, based on R, who are
expected to have more months until relapse under treatment than under standard-of-care.
Similarly,
Ω˜− =
{
ri | B˜(ri) = 0
}
(27)
yields the test-negatives subset of observations in the evaluation dataset, based on R, who are
expected to have fewer months until relapse under treatment than under standard-of-care.
C Data Example: Summary of Dataset
Table 5: Summary of Outcome and Treatment Variables
Overall (93676) Non-event (3063) Event (90613) N missing
Outcomes
No CHD within 10 years of enrollment, n (%) 90613 (97%) - - 0
No breast cancer within 10 years of enrollment, n (%) 88883 (95%) - - 0
Treatment
Currently using unopposed estrogen and/or estrogen plus progesterone, n (%) 41630 (44%) 1003 (33%) 40627 (45%) 85
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Overall (93676) Non-event (3063) Event (90613) N missing
Highest grade completed 767
None, n (%) 84 (0%) 2 (0%) 82 (0%)
1-4, n (%) 356 (0%) 11 (0%) 345 (0%)
5-8, n (%) 1121 (1%) 51 (2%) 1070 (1%)
9-11, n (%) 3288 (4%) 184 (6%) 3104 (3%)
High school, n (%) 15122 (16%) 592 (19%) 14530 (16%)
Vocational, n (%) 9123 (10%) 369 (12%) 8754 (10%)
Some college, n (%) 24812 (27%) 828 (27%) 23984 (27%)
College, n (%) 10669 (11%) 277 (9%) 10392 (12%)
Some post-graduate, n (%) 11018 (12%) 314 (10%) 10704 (12%)
Master’s, n (%) 14732 (16%) 343 (11%) 14389 (16%)
Doctoral, n (%) 2584 (3%) 67 (2%) 2517 (3%)
Ethnicity 265
American Indian or Alaskan Native, n (%) 421 (0%) 18 (1%) 403 (0%)
Asian or Pacific Islander, n (%) 2671 (3%) 52 (2%) 2619 (3%)
Black or African-American, n (%) 7635 (8%) 283 (9%) 7352 (8%)
Hispanic/Latino, n (%) 3609 (4%) 56 (2%) 3553 (4%)
White (non-Hispanic), n (%) 78016 (84%) 2611 (86%) 75405 (83%)
Other, n (%) 0 (0%) 28 (1%) 1031 (1%)
Heard about study 1281
Mailed letter, n (%) 47623 (52%) 1722 (57%) 45901 (51%)
Brochure, n (%) 9789 (11%) 317 (10%) 9472 (11%)
TV, n (%) 2731 (3%) 93 (3%) 2638 (3%)
Radio, n (%) 1017 (1%) 24 (1%) 993 (1%)
Newspaper or magaize, n (%) 14610 (16%) 415 (14%) 14195 (16%)
Meeting, n (%) 1158 (1%) 32 (1%) 1126 (1%)
Friend or relative, n (%) 9408 (10%) 223 (7%) 9185 (10%)
Other, n (%) 6059 (7%) 198 (7%) 5861 (7%)
Family income 4119
Less than $10,000, n (%) 3917 (4%) 248 (8%) 3669 (4%)
$10,000 - $19,999, n (%) 10101 (11%) 504 (17%) 9597 (11%)
$20,000 - $34,999, n (%) 20226 (23%) 838 (29%) 19388 (22%)
$35,000 - $49,999, n (%) 17430 (19%) 536 (18%) 16894 (19%)
$50,000 - $74,999, n (%) 17487 (20%) 409 (14%) 17078 (20%)
$75,000 - $99,999, n (%) 8181 (9%) 169 (6%) 8012 (9%)
$100,000 - $149,999, n (%) 6034 (7%) 73 (3%) 5961 (7%)
$150,000 or more, n (%) 3393 (4%) 42 (1%) 3351 (4%)
Don’t know, n (%) 2788 (3%) 99 (3%) 2689 (3%)
Table 6: Summary of Variables Influencing Only Treatment Assignment
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Overall (93676) Non-event (3063) Event (90613) N missing
Age, mean (IQR) 63.6 (58, 69) 68.3 (64, 73) 63.5 (57, 69) 0
Angina ever, n (%) 5547 (6%) 584 (19%) 4963 (6%) 708
Aortic aneurysm ever, n (%) 187 (0%) 30 (1%) 157 (0%) 1523
Breast cancer ever, n (%) 5299 (6%) 208 (7%) 5091 (6%) 879
Coronary bypass surgery ever, n (%) 881 (1%) 204 (7%) 677 (1%) 1513
Cancer ever, n (%) 12075 (13%) 481 (16%) 11594 (13%) 752
Cardiac catheterization ever, n (%) 3837 (4%) 453 (15%) 3384 (4%) 1513
Carotid endarterectomy/angioplasty ever, n (%) 344 (0%) 59 (2%) 285 (0%) 1510
Cervix cancer ever, n (%) 1205 (1%) 44 (1%) 1161 (1%) 916
Heart failure ever, n (%) 893 (1%) 134 (4%) 759 (1%) 7
Cadiovascular disease ever, n (%) 17523 (19%) 1206 (40%) 16317 (18%) 2045
Hysterectomy ever, n (%) 39149 (42%) 1415 (46%) 37734 (42%) 87
Diabetes ever, n (%) 5318 (6%) 544 (18%) 4774 (5%) 96
Stroke ever, n (%) 1415 (2%) 142 (5%) 1273 (1%) 56
Have a lot of energy? 772
All the time, n (%) 4740 (5%) 108 (4%) 4632 (5%)
Most the time, n (%) 33633 (36%) 766 (25%) 32867 (37%)
A good bit, n (%) 20668 (22%) 642 (21%) 20026 (22%)
Some times, n (%) 19397 (21%) 780 (26%) 18617 (21%)
A little bit, n (%) 9956 (11%) 481 (16%) 9475 (11%)
Never, n (%) 4510 (5%) 258 (9%) 4252 (5%)
General health 655
Excellent, n (%) 16576 (18%) 263 (9%) 16313 (18%)
Very good, n (%) 37684 (41%) 861 (28%) 36823 (41%)
Good, n (%) 29669 (32%) 1280 (42%) 28389 (32%)
Fair, n (%) 8210 (9%) 550 (18%) 7660 (9%)
Poor, n (%) 882 (1%) 82 (3%) 800 (1%)
High cholesterol requiring pills ever, n (%) 13773 (15%) 748 (25%) 13025 (15%) 2071
Hot flash in past 4 weeks 733
No, n (%) 15158 (16%) 386 (13%) 14772 (16%)
Mild, n (%) 4593 (5%) 139 (5%) 4454 (5%)
Moderate, n (%) 1267 (1%) 38 (1%) 1229 (1%)
Severe, n (%) 0 (0%) 0 (0%) 0 (0%)
Hypertension 1699
Never, n (%) 61196 (67%) 1270 (42%) 59926 (67%)
Yes, untreated, n (%) 7317 (8%) 338 (11%) 6979 (8%)
Yes, treated, n (%) 23464 (26%) 1392 (46%) 22072 (25%)
Recent physical/emotional problems socially 747
Not at all, n (%) 68565 (74%) 2004 (66%) 66561 (74%)
Slightly, n (%) 14249 (15%) 549 (18%) 13700 (15%)
Moderately, n (%) 6121 (7%) 279 (9%) 5842 (6%)
Quite a bit, n (%) 3217 (3%) 169 (6%) 3048 (3%)
Extremely, n (%) 777 (1%) 34 (1%) 743 (1%)
Quality of life (1-10), mean (IQR) 8.3 (8, 9) 8.1 (7, 9) 8.3 (8, 9) 724
Menopause before age 40, n (%) 8352 (9%) 339 (12%) 8013 (9%) 3951
MENPSYMP, n (%) 64608 (71%) 1922 (65%) 62686 (71%) 2425
Limited in daily activities? 726
Yes, limited a lot, n (%) 6263 (7%) 442 (15%) 5821 (6%)
Yes, limited a little, n (%) 23110 (25%) 1132 (37%) 21978 (24%)
No, not limited at all, n (%) 63577 (68%) 1459 (48%) 62118 (69%)
One or both ovaries removed 552
No, n (%) 65240 (70%) 2019 (66%) 63221 (70%)
Yes, one taken out, n (%) 6583 (7%) 217 (7%) 6366 (7%)
Yes, both taken out, n (%) 18890 (20%) 713 (23%) 18177 (20%)
Yes, unknown number taken out, n (%) 738 (1%) 29 (1%) 709 (1%)
Yes, part of ovary taken out, n (%) 893 (1%) 30 (1%) 863 (1%)
Don’t know, n (%) 780 (1%) 36 (1%) 744 (1%)
Osteoporosis ever, n (%) 8282 (9%) 385 (13%) 7897 (9%) 1240
Any part of ovaries removed before age 40, n (%) 8279 (9%) 301 (10%) 7978 (9%) 1120
Peripheral arterial disease ever, n (%) 2084 (2%) 249 (8%) 1835 (2%) 784
Pregnant ever, n (%) 84005 (90%) 2760 (90%) 81245 (90%) 315
Angioplasty of coronary arteries ever, n (%) 1128 (1%) 177 (6%) 951 (1%) 1509
Stroke ever, n (%) 1415 (2%) 142 (5%) 1273 (1%) 56
Health limits vigorous activities 812
Yes, limited a lot, n (%) 30022 (32%) 1542 (51%) 28480 (32%)
Yes, limited a little, n (%) 41367 (45%) 1162 (38%) 40205 (45%)
No, not limited at all, n (%) 21475 (23%) 328 (11%) 21147 (24%)
Table 7: Summary of Variables Influencing Treatment Assignment and Rule
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